The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1746
January 19, 2026
View Complete Issue         Table of Contents 2019 
Donidalorsen (Dawnzera) for Prevention of Hereditary Angioedema Attacks
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Donidalorsen (Dawnzera) for Prevention of Hereditary Angioedema Attacks
January 19, 2026 (Issue: 1746)
Donidalorsen (Dawnzera – Ionis), a subcutaneously injected prekallikrein-directed antisense oligonucleotide, has been approved by the FDA for prevention of hereditary angioedema (HAE) attacks in patients ≥12 years old. It is the first...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Donidalorsen (Dawnzera) for Prevention of Hereditary Angioedema Attacks
Article code: 1746c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.